ArticleBMC pregnancy and childbirth2025
Risk of intrauterine transmission and pregnancy outcomes following SARS-CoV-2 infection in the first or second trimester: a prospective cohort study.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundChina encountered a nation-wide outbreak of SARS-CoV-2 transmission during December 2022-January 2023 after discontinuation of the strict zero-Covid-19 policy on December 7, 2022. However, data on its impact on early pregnancy was limited. We aimed to investigate the risk of intrauterine transmission and pregnancy outcomes following SARS-CoV-2 infection during the first or second trimester, and to assess the safety of post-infection amniocentesis.
methodsFrom January 31 to February 28, 2023, we prospectively invited all pregnant women who were referred for amniocentesis to perform chromosomal microarray analysis to participate in this study. Based on the infection time, the participants were divided into group one with Covid-19 in the first trimester and and group two with Covid-19 in the second trimester. Amniotic fluid samples were analyzed for SARS-CoV-2 RNA using qRT-PCR. Pregnancy and neonatal outcomes were assessed through obstetric ultrasound examination and follow-ups.
resultsIn total, 225 women with 239 fetuses (14 sets of twin pregnancy) underwent amniocentesis in the study period. Finally, 134 pregnant women (6 sets of twin pregnancy) were included. They were infected with SARS-CoV-2 at gestational age 3 to 25 weeks. Amniocentesis was performed at gestational age 17 to 33 weeks. None of the 140 amniotic fluid samples tested positive for SARS-CoV-2 RNA, indicating no intrauterine transmission. Rates of premature delivery (8.8%) and birth weight (3335.8 g vs. 3279.9 g, p = 0.607) did not differ significantly between the first and second trimester infection groups.
conclusionNo evidence of vertical transmission or adverse pregnancy outcomes was observed following SARS-CoV-2 infection during the first or second trimesters. Amniocentesis beyond the acute phase of infection appears safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.